Pioneering Innovation in Global Healthcare
Novartis AG, headquartered in Basel, Switzerland, stands as a global leader in the pharmaceutical industry, committed to reimagining medicine to improve and extend people’s lives. With a presence in over 155 countries, Novartis focuses on innovative medicines across various therapeutic areas, including oncology, neuroscience, immunology, and cardiovascular diseases.
A Legacy of Innovation
Formed in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis’s roots trace back over 250 years, beginning with the production of synthetic dyes and evolving into a pharmaceutical powerhouse. The company’s rich history is marked by a continuous pursuit of scientific advancement and a commitment to addressing some of the world’s most pressing health challenges.
Leadership and Vision
Under the leadership of Vasant (Vas) Narasimhan, M.D., who became CEO in 2018, Novartis has intensified its focus on cutting-edge therapies, including gene therapy, cell therapy, and radioligand therapy. Dr. Narasimhan’s vision emphasizes data-driven decision-making, ethical business practices, and a patient-centric approach to innovation.
Global Impact and Commitment
Novartis’s medicines reach over 250 million people worldwide annually, reflecting the company’s dedication to global health. Beyond its commercial endeavors, Novartis invests in numerous programs aimed at expanding access to healthcare in underserved regions, reinforcing its role as a responsible corporate citizen.
Embracing the Future
With substantial investments in research and development, Novartis continues to explore new frontiers in medicine. The company’s commitment to innovation is evident in its pursuit of novel therapies and its strategic collaborations aimed at accelerating the development of life-saving treatments.
